Sus­pi­cious re­turns trig­ger in­sid­er trad­ing suit fol­low­ing $11.6B Biover­a­tiv deal

Reg­u­la­tors at the SEC are sound­ing an alarm fol­low­ing sus­pi­cious trad­ing ac­tiv­i­ty that went down days be­fore Sanofi’s $11.6 bil­lion buy­out of he­mo­phil­ia drug­mak­er Biover­a­tiv …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER